$113.05
2.06% today
NYSE, Apr 03, 06:46 pm CET
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Novartis ADR Stock price

$110.77
+0.15 0.14% 1M
-3.70 3.23% 6M
+13.46 13.83% YTD
+16.36 17.33% 1Y
+28.10 33.99% 3Y
+31.63 39.96% 5Y
+16.31 17.27% 10Y
NYSE, Closing price Wed, Apr 02 2025
+1.16 1.06%
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Key metrics

Market capitalization $210.19b
Enterprise Value $228.08b
P/E (TTM) P/E ratio 18.73
EV/FCF (TTM) EV/FCF 14.03
EV/Sales (TTM) EV/Sales 4.53
P/S ratio (TTM) P/S ratio 4.18
P/B ratio (TTM) P/B ratio 4.97
Dividend yield 3.49%
Last dividend (FY25) $3.87
Revenue growth (TTM) Revenue growth 1.08%
Revenue (TTM) Revenue $50.32b
EBIT (operating result TTM) EBIT $15.41b
Free Cash Flow (TTM) Free Cash Flow $16.25b
Cash position $13.46b
EPS (TTM) EPS $5.91
P/E forward 16.74
P/S forward 3.96
EV/Sales forward 4.30
Short interest 0.20%
Show more

Is Novartis ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Novartis ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Novartis ADR forecast:

5x Buy
18%
19x Hold
68%
4x Sell
14%

Analyst Opinions

28 Analysts have issued a Novartis ADR forecast:

Buy
18%
Hold
68%
Sell
14%

Financial data from Novartis ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
50,317 50,317
1% 1%
100%
- Direct Costs 13,045 13,045
10% 10%
26%
37,272 37,272
6% 6%
74%
- Selling and Administrative Expenses 6,497 6,497
26% 26%
13%
- Research and Development Expense 9,301 9,301
8% 8%
18%
21,474 21,474
0% 0%
43%
- Depreciation and Amortization 6,069 6,069
29% 29%
12%
EBIT (Operating Income) EBIT 15,405 15,405
19% 19%
31%
Net Profit 11,941 11,941
20% 20%
24%

In millions USD.

Don't miss a Thing! We will send you all news about Novartis ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis ADR Stock News

Positive
Investors Business Daily
about 4 hours ago
Novartis stock popped Thursday — prompting Travere Therapeutics to slide — after winning FDA approval for a kidney disease treatment. The post Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval appeared first on Investor's Business Daily.
Neutral
CNBC
about 7 hours ago
Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting. The Trump administration is considering a so-called 232 investigation into pharmaceuticals, which could lead to import duties, according to a Bloomberg report.
Neutral
PRNewsWire
about 17 hours ago
Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed Vanrafia achieved proteinuria reduction of 36.1% (P
More Novartis ADR News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 75,883
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today